The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...
Exploring withdrawal risks, symptom variability, and safer discontinuation strategies Many people are surprised by how ...
New athletic shoes promise to boost focus by stimulating feet. Neuroscience reveals the connection is complex. While feet have many sensors, this input mainly affects body awareness. Claims of ...
To boost morning energy, there are a number of low-effort evening habits you can start implementing–even if you don't get enough sleep every night.
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that ...
Taking certain antidepressants at the time of a traumatic brain injury (TBI) is not associated with an increased risk of ...
GlobalData on MSN
FDA accepts Otsuka’s centanafadine application for ADHD treatment
The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.
Otsuka Pharmaceutical announced that the FDA is reviewing investigational centanafadine -- a potential first-in-class ...
Your feet can send a lot of sensory information to your brain. But whether you believe that your footwear is affecting your ...
The Food and Drug Administration (FDA) has accepted for priority review Japanese drugmaker Otsuka’s (TYO: 4578) New Drug ...
The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results